9 research outputs found
Additional file 1: of Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction
eTable 1. The care facilities of study subjects during the index acute myocardial infarction. eTable 2. Relative risks of various clinical outcomes in patients receiving different antiplatelet therapies using shared frailty model controlling for 174 individual hospitals. eTable 3. Relative risks of various clinical outcomes in patients receiving different antiplatelet therapies using shared frailty model controlling for 11 different levels of hospitals. (DOCX 20 kb
Multivariate logistic regression for having at least one drug as potentially inappropriate.
<p>*<i>P</i><0.05,</p><p>**<i>P</i><0.01,</p><p>***<i>P</i><0.001.</p
Clinic visit-level bivariate analysis (N = 605239) according to the three sets of potentially inappropriate medication criteria.
<p>Abbreviations: MD- Medical Doctor, NTD- New Taiwan dollar.</p><p>***<i>P</i><0.001.</p
Multivariate logistic regression for having at least one potentially inappropriate medication in one clinic visit.
<p>***<i>P</i><0.0001.</p
Characteristics of the three sets of explicit criteria and their performance in detecting potentially inappropriate medications.
<p>*Statements are those for potentially inappropriate medications without considering drug-disease or drug-syndrome interactions.</p
The leading ten potentially inappropriate medications (PIMs) identified in 2,428,222 prescribed medications.
<p>Beers criteria- 2012 version of Beers criteria, PIM-Taiwan criteria- potentially inappropriate medication Taiwan criteria.</p><p>*Zolpidem is considered as PIMs if daily dose is more than 5 mg in PRISCUS criteria but as PIMs regardless of daily dose in 2012 version of Beers criteria.</p
Patient-level bivariate analysis (N = 25187) by the presence of least one PIM according to the three sets of potentially inappropriate medication criteria.
<p>***<i>P</i><0.0001.</p
Basic characteristics of the home healthcare recipients.
<p>Basic characteristics of the home healthcare recipients.</p
PEGylation Site-Dependent Structural Heterogeneity Study of MonoPEGylated Human Parathyroid Hormone Fragment hPTH(1–34)
The structures of C- and N-terminally
monoPEGylated human parathyroid
hormone fragment hPTH(1–34) as well as their unmodified counterparts,
polyÂ(ethylene glycol) (PEG) and hPTH(1–34), have been studied
by small-angle neutron scattering (SANS). The scattering results show
that free hPTH(1–34) in 100 mM phosphate buffer (pH 7.4) aggregates
into clusters. After conjugation with PEG, the PEG–peptide
conjugates self-assemble into a supramolecular core–shell structure
with a cylindrical shape. The PEG chains form a shell around the hPTHÂ(1–34)
core to shield hPTH(1–34) from the solvent. The detailed structural
information on the self-assembled structures is extracted from SANS
using a model of the cylindrical core with a shell of Gaussian chains
attached to the core surface. On the basis of the data, because of
the charge–dipole interactions between the conjugated PEG chain
and the peptide, the conjugated PEG chain forms a more collapsed conformation
compared to free PEG. Moreover, the size of the self-assembled structures
formed by the C-terminally monoPEGylated hPTHÂ(1–34) is about
3 times larger than that of the N-terminally monoPEGylated hPTH(1–34).
The different aggregation numbers of the self-assembled structures,
triggered by different PEGylation sites, are reported. These size
discrepancies because of different PEGylation sites could potentially
affect the pharmacokinetics of the hPTH(1–34) drug